TGTX
TG Therapeutics, Inc.30.79
-0.62-1.97%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Record NPS amid conservative guide
Q&A reinforced Briumvi's momentum but spotlighted record new patient starts—the highest since launch—across sites, countering Roche subcu pressure with steady IV share gains and no Ocrevus switch erosion. Management called 2026 guidance conservative, baking in Q1 gross-to-net headwinds yet signaling upside from persistence out to week 96. Subcu commercialization requires low incremental costs via 80% field overlap; early DTC metrics exceeded expectations. Demand is firing on all cylinders. Confident tone persists, but investors will track ENHANCE data and subcu readout.
Key Stats
Market Cap
4.89BP/E (TTM)
11.12Basic EPS (TTM)
2.77Dividend Yield
0%Recent Filings
10-K
FY2025 results
TG Therapeutics delivered explosive FY2025 growth, with BRIUMVI net product revenue rocketing 93% y/y to $606.9M, powered by U.S. sales surging to $594.1M while ex-U.S. partner shipments doubled to $12.8M. Q4 momentum accelerated as pre-approval inventory depleted, normalizing gross margins after elevated R&D expensing; yet cost of revenue climbed to $100.7M on royalties and a $6.2M batch reserve. Pipeline advanced with 75% enrollment in subQ ublituximab Phase 3 and completed IV dosing trial enrollment. $250M Blue Owl debt funds ops through 2029; $100M buyback completed. Valuation allowance released on $348M deferred tax asset. Supply disruptions from third-party manufacturing pose quarterly risks.
8-K
BRIUMVI revenue surges
TG Therapeutics reported Q4 2025 total revenue of $192.6 million, up from $108.2 million prior year, driven by BRIUMVI U.S. net sales hitting $182.7 million—20% quarterly growth. Full-year revenue soared to $616.3 million, with 92% BRIUMVI growth. BRIUMVI booms. Guidance targets $875-900 million global revenue in 2026, yet pipeline milestones like ENHANCE data loom mid-year.
8-K
BRIUMVI revenue soars
TG Therapeutics reported preliminary 2025 global revenue of ~$616M, driven by BRIUMVI U.S. net product sales of ~$594M, with Q4 at ~$182M. Company guides 2026 total revenue to $875-900M, including BRIUMVI U.S. at $825-850M, while targeting $350M operating expenses. BRIUMVI crushed targets. Key milestones include ENHANCE IV data mid-2026 and subcutaneous topline year-end.
10-Q
Q3 FY2025 results
TG Therapeutics crushed Q3 with product revenue rocketing 91% y/y to $159.3M on BRIUMVI strength, driving total revenue up 93% to $161.7M and operating income to $29.4M from $12.4M. Gross margins held firm as cost of revenue scaled with sales; diluted EPS leaped to $2.43 from $0.02, backed by 161M shares. Cash and investments dipped to $180M amid $91M treasury buys completing a $100M program, yet $245M debt remains comfy at low-single-digit SOFR plus margin through 2029. No FCF as capex tiny. Solid runway persists. BRIUMVI faces stiff competition.
8-K
BRIUMVI revenue soars
TG Therapeutics reported third-quarter 2025 total revenue of $161.7 million, driven by BRIUMVI U.S. net sales of $152.9 million, up 84% from last year. The company raised its full-year BRIUMVI U.S. guidance to $585 million, reflecting robust demand, while advancing Phase 3 trials for subcutaneous ublituximab and simplified IV dosing. It completed a $100 million share repurchase and authorized another. Cash stands at $178.3 million, sufficient for operations. Revenue momentum surges.
IPO
Employees
Sector
Industry
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BIIB
Biogen Inc.
171.50-4.24
FBRX
Forte Biosciences, Inc.
23.27+1.31
GLPG
Galapagos NV
31.08-0.03
IMTX
Immatics N.V.
10.09+0.11
MGNX
MacroGenics, Inc.
1.35-0.02
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
ONC
BeOne Medicines Ltd.
304.31-6.36
TOVX
Theriva Biologics, Inc.
0.21+0.01